Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Adenocarcinoma 1Breast Neoplasms 1

Interventions

Gemcitabine 5Taxes 3Albumin-Bound Paclitaxel 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2Oxaliplatin 2Losartan 2Leucovorin 2Irinotecan 2Fluorouracil 2130-nm albumin-bound paclitaxel 2tocilizumab 1selicrelumab 1niraparib 1durvalumab 1dehydroftorafur 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Standard of Care 1Specimen Handling 1Radiation 1Panitumumab 1Pancreaticoduodenectomy 1PEGPH20 1Optical Imaging 1Nivolumab 1Metformin 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × selicrelumab × 1 year × Clear all
NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡